Compare BEAM & UAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAM | UAA |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | 14400 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.6B |
| IPO Year | 2019 | N/A |
| Metric | BEAM | UAA |
|---|---|---|
| Price | $28.62 | $5.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 16 |
| Target Price | ★ $50.75 | $6.48 |
| AVG Volume (30 Days) | 1.9M | ★ 8.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.77 | $1.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 33.33 | N/A |
| 52 Week Low | $15.60 | $4.13 |
| 52 Week High | $36.44 | $8.15 |
| Indicator | BEAM | UAA |
|---|---|---|
| Relative Strength Index (RSI) | 45.77 | 32.23 |
| Support Level | $28.50 | $4.76 |
| Resistance Level | $29.06 | $6.71 |
| Average True Range (ATR) | 2.02 | 0.26 |
| MACD | -0.31 | -0.15 |
| Stochastic Oscillator | 5.27 | 17.58 |
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.